- Title: Subtitle
- Extended Follow-Up Beyond 2 .5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
- Creators
- Yasmin H. Karimi - U-M Rogel Cancer CenterCatherine Thieblemont - Assistance Publique – Hôpitaux de ParisHerve Ghesquieres - Hospices Civils de LyonChan Y. Cheah - University of Western AustraliaMichael Roost Clausen - Vejle SygehusDavid Cunningham - Royal Marsden NHS Foundation TrustWojciech Jurczak - The Maria Sklodowska-Curie National Research Institute of OncologyKim M. Linton - University of ManchesterMartin Hutchings - University of CopenhagenTycel Phillips - U-M Rogel Cancer CenterUmar Farooq - University of IowaWon Seog Kim - Samsung Medical CenterMinh H. Dinh - AbbVieJagannath Ghosh - GenmabRajash Pallai - GenmabMonica Wielgos-Bonvallet - GenmabChristian Eskelund - GenmabPieternella J. Lugtenburg - Erasmus MCJulie M. Vose - University of Nebraska Medical Center
- Resource Type
- Abstract
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.24(Supplement 1), pp.S212-S212
- Publisher
- Elsevier Inc
- DOI
- 10.1016/S2152-2650(24)00791-2
- ISSN
- 2152-2650
- Language
- English
- Date published
- 09/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984699514502771
Abstract
Extended Follow-Up Beyond 2 .5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
Clinical lymphoma, myeloma and leukemia, Vol.24(Supplement 1), pp.S212-S212
09/2024
DOI: 10.1016/S2152-2650(24)00791-2
Details
Metrics
7 Record Views